医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DaVita Expands Operations in Malaysia

2013年07月22日 PM07:25
このエントリーをはてなブックマークに追加


 

DENVER

DaVita®, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced the acquisition of the dialysis operations of Malaysia’s Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd.

“This is an important move for DaVita in the Asia-Pacific region,” said Dennis Kogod, chief operating officer of DaVita HealthCare PartnersTM. “Scaling up operations in Malaysia allows us to bring outstanding quality of care to this region.”

With the addition of CDC Group’s 18 centers, DaVita now operates a total of 21 centers in Malaysia with plans to expand in the coming years.

“We’re excited to build on the reputation of CDC Group and to welcome the teammates and patients from their 18 centers to DaVita,” said Atul Mathur, president of DaVita’s Asia-Pacific operations. “Malaysia is a key market for our growth strategy in the Asia-Pacific region where we are now serving patients in five countries.”

DaVita has improved clinical outcomes 13 years in a row in the United States and has consistently demonstrated clinical results that are the best or among the best in virtually every category in the kidney care industry. These outcomes help drive lower mortality rates and fewer hospitalizations, directly supporting DaVita’s aim to improve patients’ health and quality of life.

“We always have been dedicated to delivering quality care to our patients, and we constantly seek opportunities to improve the care they receive,” said Dr. Ong Kee Liang, founding nephrologist of CDC Group. “With DaVita’s impressive record of improved clinical outcomes coming to the patients in our centers, we believe it is our patients who are the true beneficiaries of this transaction.”

For more information, visit DaVita.com.

DaVita and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita HealthCare Partners Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2013, DaVita operated or provided administrative services at 1,991 outpatient dialysis centers located in the United States serving approximately 156,000 patients. The company also operated 41 outpatient dialysis centers located in nine countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to anticipated and prospective growth of certain of our international ventures, the clinical outcomes that they will deliver and our growth strategy for the Asia-Pacific region. Factors which could impact future results include the risks and uncertainties associated with expansion of our operations and services to markets outside the United States, governmental regulations, general economic and other market conditions, competition, and the risk factors set forth in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent quarterly reports filed on Form 10-Q. The forward-looking statements should be considered in light of these risks and uncertainties. We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

CONTACT

DaVita
Media:
David Tauchen, 303-876-2802
David.Tauchen@davita.com

同じカテゴリーの記事 

  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携